Abstract:Abstract Introduction: Despite the numerous drugs available for patients with metastatic colorectal cancer (mCRC), median overall survival for this group of patients remains at ~20-24 months, with no significant advances in the last 7 years. In the US ~50,000 patients die each year from mCRC refractory to systemic therapy. Inhibiting angiogenesis as a therapy has led to a great deal of enthusiasm. However, the overall benefit of classical-antiangiogenic therapy remains modest and has not lived up to their expectations in treating CRC. Our recent studies suggest that VEGF intracrine signaling, rather than autocrine/paracrine signaling, regulates cell survival in CRC cells. Further studies to understand the significance and mechanisms of this novel function have led us to identify factors that intracellularly interact with VEGF. Our studies further indicate that one such interacting protein, SPECC1L, may have a significant role in CRC cell proliferation and may be a potential target in mCRC therapy. Methods: Lysates from CRC cells expressing Myc-tagged VEGF protein were immunoprecipitated and analyzed by mass spectrometry to identify VEGF-interacting protiens. SPECC1L was identified as a co-precipitated protein with high level of confidence. SPECC1L was depleted using siRNA and effects of such depletion on CRC cell growth and morphology were measured by cell growth assays (MTT), microscopy, FACS and western blot analyses. Localization of the protein and its interaction with microtubules and actin were visualized by immunostaining of FLAG-tagged recombinant SPECC1L protein. Results: SPECC1L was identified as a protein that co-immunoprecipitated with Myc-tagged VEGF in CRC cells using mass spectroscopy. Previous literature suggests a role for SPECC1L in cell division. As a fraction of VEGF overexpressing CRC cells have a large multinucleated phenotype, likely arising due to defects in cell division, it was hypothesized that a VEGF mediated regulation of SPECC1L may lead to such phenotype. Depletion of SPECC1L by siRNAs in multiple CRC cell lines led to strong defects in cell division. The effects of SPECC1L depletion were manifested as accumulation of doublet-cells failing to complete cytokinesis following mitosis and resulted in reduced cell proliferation. Failure to complete cell division also led to the formation of multinucleated cells and enhanced cell death. Conclusions: Inhibition of SPECC1L strongly inhibits CRC cell proliferation and enhances cell death. Thus targeting SPECC1L has the potential for developing therapeutics that reduce viability of CRC cells and improve survival of colorectal cancer patients. *** These studies were supported by the Gillson-Longenbaugh Foundation. Citation Format: Rajat Bhattacharya, Ling Xia, Fan Fan, Rui Wang, Delphine Boulbes, Xiang-Cang Ye, David Hawke, Lee Ellis. Depletion of SPECC1L inhibits colorectal cancer cell proliferation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3474. doi:10.1158/1538-7445.AM2017-3474

Suppression of cellular apoptosis susceptibility (CSE1L) inhibits proliferation and induces apoptosis in colorectal cancer cells.

Abstract 3474: Depletion of SPECC1L Inhibits Colorectal Cancer Cell Proliferation

Silencing Of Cxcr7 Gene Represses Growth And Invasion And Induces Apoptosis In Colorectal Cancer Through Erk And Beta-Arrestin Pathways

[Lentivirus-mediated siRNA targeting sae1 induces cell cycle arrest and apop- tosis in colon cancer cell RKO].

Downregulation of Smc1a Inhibits Growth and Increases Apoptosis and Chemosensitivity of Colorectal Cancer Cells

CSE1L participates in regulating cell mitosis in human seminoma.

The role of CSE1L silencing in the regulation of proliferation and apoptosis via the AMPK/mTOR signaling pathway in chronic myeloid leukemia

Upregulation of CPE promotes cell proliferation and tumorigenicity in colorectal cancer

CSE1L Silencing Impairs Tumor Progression Via MET/STAT3/PD-L1 Signaling in Lung Cancer.

CSE1L, As a Novel Prognostic Marker, Promotes Pancreatic Cancer Proliferation by Regulating the AKT/mTOR Signaling Pathway

Circ_cse1l Inhibits Colorectal Cancer Proliferation by Binding to Eif4a3

Down-regulation of lncRNA CCAT 1 inhibits colon cancer cell proliferation and promotes apoptosis by targeting apoptosis-related proteins

Knockdown of SLC39A7 Inhibits Cell Growth and Induces Apoptosis in Human Colorectal Cancer Cells

Effects of Cyclin-Dependent Kinase 8 Specific Sirna on the Proliferation and Apoptosis of Colon Cancer Cells

RRS1 Silencing Suppresses Colorectal Cancer Cell Proliferation and Tumorigenesis by Inhibiting G2/M Progression and Angiogenesis

Sm-like 5 knockdown inhibits proliferation and promotes apoptosis of colon cancer cells by upregulating p53, CDKN1A and TNFRSF10B

Effect of targeted mammalian sterile 20-like kinase 1 regulation on proliferation and apoptosis of SW480 colorectal cancer cells

SUMO-specific Protease 1 Regulates the in Vitro and in Vivo Growth of Colon Cancer Cells with the Upregulated Expression of CDK Inhibitors.

Knockdown of ribosomal protein L22-like 1 arrests the cell cycle and promotes apoptosis in colorectal cancer

Selenium‐binding protein 1 inhibits malignant progression and induces apoptosis via distinct mechanisms in non‐small cell lung cancer

SMC1 promotes proliferation and inhibits apoptosis through the NF‑κB signaling pathway in colorectal cancer.